These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 15686707)

  • 21. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
    Brady RL; Green K; Frei C; Maxwell P
    Transpl Infect Dis; 2009 Apr; 11(2):106-11. PubMed ID: 19054381
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.
    Doesch AO; Repp J; Hofmann N; Erbel C; Frankenstein L; Gleissner CA; Schmidt C; Ruhparwar A; Zugck C; Schnitzler P; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2012; 6():289-95. PubMed ID: 23091373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: a single center experience.
    Babel N; Gabdrakhmanova L; Juergensen JS; Eibl N; Hoerstrup J; Hammer M; Rosenberger C; Hoeflich C; Frei U; Rohde F; Volk HD; Reinke P
    Transplantation; 2004 Jul; 78(2):283-5. PubMed ID: 15280691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
    Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation.
    Avidan YP; Paul M; Rahamimov R; Bishara J; Samra Z; Edna S; Mor E
    J Infect; 2008 Sep; 57(3):236-40. PubMed ID: 18674820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.
    Akalin E; Sehgal V; Ames S; Hossain S; Daly L; Barbara M; Bromberg JS
    Am J Transplant; 2003 Jun; 3(6):731-5. PubMed ID: 12780565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T; Opatrny K; Bouda M; Treska V; Jindra P; Svecova M
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
    Fayek SA; Beshears E; Lieber R; Alvey N; Sauer A; Poirier J; Hollinger EF; Olaitan OK; Jensik S; Geyston J; Brokhof MM; Hodowanec AC; Hertl M; Simon DM
    Transplant Proc; 2016; 48(6):2056-2064.e1. PubMed ID: 27569944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation.
    Lopau K; Greser A; Wanner C
    Clin Transplant; 2007; 21(1):80-5. PubMed ID: 17302595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
    Lautenschlager I; Loginov R; Mäkisalo H; Höckerstedt K
    J Clin Virol; 2015 Oct; 71():73-5. PubMed ID: 26318605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.
    McKeen JT; Tsapepas DS; Li H; Anamisis A; Martin ST
    Prog Transplant; 2015 Mar; 25(1):39-44. PubMed ID: 25758799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
    Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
    Bedel AN; Hemmelgarn TS; Kohli R
    Liver Transpl; 2012 Mar; 18(3):347-54. PubMed ID: 22139888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM; Subramaniam S
    Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of Late-Onset Cytomegalovirus Infection and Disease in Donor-Positive/Recipient-Negative Kidney Transplant Recipients Using Low-Dose Valganciclovir.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018; 50(1):124-129. PubMed ID: 29407294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
    Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
    Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
    Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prophylactic and pre-emptive therapy for cytomegalovirus infection in kidney transplant patients using oral valganciclovir].
    Guirado L; Rabella N; Díaz JM; Facundo C; Maderuelo A; Margall N; Silva I; García-Maset R; Calabia J; Giménez I; Garra N; Solà R; Ballarín JA
    Nefrologia; 2008; 28(3):293-300. PubMed ID: 18590496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.